Premium
INTRAVENOUS IRON IN CHRONIC KIDNEY DISEASE: HAEMOGLOBIN CHANGE SHORTLY AFTER TREATMENT OF PATIENTS NEITHER ON DIALYSIS NOR ON ERYTHROPOIETIN
Author(s) -
Tagboto Senyo,
Cropper Liz,
Mostafa Samiul,
Turner June,
Bailey Georgina,
PughClarke Karen
Publication year - 2008
Publication title -
journal of renal care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.381
H-Index - 27
eISSN - 1755-6686
pISSN - 1755-6678
DOI - 10.1111/j.1755-6686.2008.00026.x
Subject(s) - medicine , erythropoietin , transferrin saturation , ferritin , kidney disease , dialysis , iron deficiency , anemia , gastroenterology , chronic renal disease
SUMMARY Anaemia is a common in chronic kidney disease. Although erythropoietin and iron supplementation are established treatments, knowledge on the use of IV iron alone in patients not on dialysis or erythropoietin is incomplete. The responses of 82 patients referred to the renal anaemia service with haemoglobin of 11.5 g/dl or less were assessed 1 week after completing four once weekly doses of 200 mg of venofer. No patients were on dialysis or erythropoietin. The haemoglobin rise 1 week after treatment was 0.53 g/dl. Ferritin levels improved from 110.8 to 410.2 ng/l and transferrin saturation from 17.7 to 27.3%. Ferritin levels remained below our target range (200–500 ng/l) in 7.7% while 25.6% had levels above this. Ferritin levels remained less than 800 ng/l in nearly all patients. Intravenous iron is cost effective and should be considered for use in patients with renal anaemia. Patients with CKD stage 5 appeared to respond less well.